List of Tables
Table 1. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Competitive Situation by Manufacturers in 2025
Table 4. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Small Molecule Multi-target Angiogenesis Inhibitor Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Small Molecule Multi-target Angiogenesis Inhibitor, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Product Types and Applications
Table 12. Global Key Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Small Molecule Multi-target Angiogenesis Inhibitor Companies by Tier (Tier 1, Tier 2, Tier 3), based on Small Molecule Multi-target Angiogenesis Inhibitor Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (K Units), 2021–2026
Table 18. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region (2021–2026)
Table 19. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (K Units), 2027–2032
Table 20. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region (2027–2032)
Table 21. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (US$ Million), 2021–2026
Table 22. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2021–2026)
Table 23. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (US$ Million), 2027–2032
Table 24. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2027–2032)
Table 25. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2021–2026
Table 27. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2027–2032
Table 28. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2021–2026
Table 29. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2021–2026
Table 32. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2027–2032
Table 33. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2021–2026
Table 42. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2027–2032
Table 43. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (US$ Million), 2027–2032
Table 50. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) by Type (2021–2026)
Table 51. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) by Type (2027–2032)
Table 52. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2021–2026)
Table 53. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2027–2032)
Table 54. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2021–2026)
Table 57. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2027–2032)
Table 58. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Type (2021–2026)
Table 59. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Type (2027–2032)
Table 60. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) by Application (2021–2026)
Table 61. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) by Application (2027–2032)
Table 62. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2021–2026)
Table 63. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2027–2032)
Table 64. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2021–2026)
Table 67. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2027–2032)
Table 68. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Application (2021–2026)
Table 69. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Application (2027–2032)
Table 70. Bayer Company Information
Table 71. Bayer Description and Business Overview
Table 72. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 74. Bayer Recent Developments/Updates
Table 75. Teva Company Information
Table 76. Teva Description and Business Overview
Table 77. Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Teva Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 79. Teva Recent Developments/Updates
Table 80. TWi Pharmaceuticals Company Information
Table 81. TWi Pharmaceuticals Description and Business Overview
Table 82. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 84. TWi Pharmaceuticals Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Novartis Company Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 94. Novartis Recent Developments/Updates
Table 95. AstraZeneca. Company Information
Table 96. AstraZeneca. Description and Business Overview
Table 97. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 99. AstraZeneca. Recent Developments/Updates
Table 100. Sanofi Company Information
Table 101. Sanofi Description and Business Overview
Table 102. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 104. Sanofi Recent Developments/Updates
Table 105. Exelixis Company Information
Table 106. Exelixis Description and Business Overview
Table 107. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 109. Exelixis Recent Developments/Updates
Table 110. Boehringer Ingelheim Company Information
Table 111. Boehringer Ingelheim Description and Business Overview
Table 112. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 114. Boehringer Ingelheim Recent Developments/Updates
Table 115. Eisai Company Information
Table 116. Eisai Description and Business Overview
Table 117. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 119. Eisai Recent Developments/Updates
Table 120. Janssen Biotech Company Information
Table 121. Janssen Biotech Description and Business Overview
Table 122. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 124. Janssen Biotech Recent Developments/Updates
Table 125. Jiangsu Hengrui Pharmaceuticals Company Information
Table 126. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 127. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 129. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 130. Chia Tai Tianqing Company Information
Table 131. Chia Tai Tianqing Description and Business Overview
Table 132. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product
Table 134. Chia Tai Tianqing Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Small Molecule Multi-target Angiogenesis Inhibitor Distributors List
Table 138. Small Molecule Multi-target Angiogenesis Inhibitor Customers List
Table 139. Small Molecule Multi-target Angiogenesis Inhibitor Market Trends
Table 140. Small Molecule Multi-target Angiogenesis Inhibitor Market Drivers
Table 141. Small Molecule Multi-target Angiogenesis Inhibitor Market Challenges
Table 142. Small Molecule Multi-target Angiogenesis Inhibitor Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Small Molecule Multi-target Angiogenesis Inhibitor
Figure 2. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Type: 2025 & 2032
Figure 4. Sorafenib Product Picture
Figure 5. Sunitinib Product Picture
Figure 6. Apatinib Product Picture
Figure 7. Anlotinib Product Picture
Figure 8. Lenvatinib Product Picture
Figure 9. Vandetanib Product Picture
Figure 10. Cabozantinib Product Picture
Figure 11. Pazopanib Product Picture
Figure 12. Axitinib Product Picture
Figure 13. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Value by Application (US$ Million), 2021–2032
Figure 14. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Application: 2025 & 2032
Figure 15. Cancer Therapy
Figure 16. Ophthalmic Diseases
Figure 17. Inflammatory and Autoimmune Diseases
Figure 18. Other
Figure 19. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size (US$ Million), 2021–2032
Figure 21. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), 2021–2032
Figure 22. Global Small Molecule Multi-target Angiogenesis Inhibitor Average Price (US$/Unit), 2021–2032
Figure 23. Small Molecule Multi-target Angiogenesis Inhibitor Report Years Considered
Figure 24. Small Molecule Multi-target Angiogenesis Inhibitor Sales Share by Manufacturers in 2025
Figure 25. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Manufacturers in 2025
Figure 26. Top 5 and Top 10 Global Small Molecule Multi-target Angiogenesis Inhibitor Players: Market Share by Revenue in Small Molecule Multi-target Angiogenesis Inhibitor in 2025
Figure 27. Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 28. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 29. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021–2032)
Figure 30. North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021–2032)
Figure 31. United States Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Canada Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021–2032)
Figure 34. Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021–2032)
Figure 35. Germany Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. France Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. U.K. Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Italy Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Russia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region (2021–2032)
Figure 41. Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2021–2032)
Figure 42. China Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Japan Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. South Korea Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. India Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Australia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. China Taiwan Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Southeast Asia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021–2032)
Figure 50. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021–2032)
Figure 51. Mexico Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Brazil Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Argentina Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Colombia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021–2032)
Figure 56. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Country (2021–2032)
Figure 57. Turkey Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Saudi Arabia Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. UAE Small Molecule Multi-target Angiogenesis Inhibitor Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Global Sales Market Share of Small Molecule Multi-target Angiogenesis Inhibitor by Type (2021–2032)
Figure 61. Global Revenue Market Share of Small Molecule Multi-target Angiogenesis Inhibitor by Type (2021–2032)
Figure 62. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Type (2021–2032)
Figure 63. Global Sales Market Share of Small Molecule Multi-target Angiogenesis Inhibitor by Application (2021–2032)
Figure 64. Global Revenue Market Share of Small Molecule Multi-target Angiogenesis Inhibitor by Application (2021–2032)
Figure 65. Global Small Molecule Multi-target Angiogenesis Inhibitor Price (US$/Unit) by Application (2021–2032)
Figure 66. Small Molecule Multi-target Angiogenesis Inhibitor Value Chain
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
